Karyopharm Therapeutics (KPTI) Stock Forecast, Price Target & Predictions
KPTI Stock Forecast
Karyopharm Therapeutics stock forecast is as follows: an average price target of $7.33 (represents a 842.64% upside from KPTI’s last price of $0.78) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KPTI Price Target
KPTI Analyst Ratings
Buy
Karyopharm Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 10, 2024 | Brian Abrahams | RBC Capital | $3.00 | $0.95 | 215.42% | 285.80% |
Jan 10, 2023 | - | Leerink Partners | $5.00 | $2.84 | 76.06% | 543.00% |
Aug 23, 2022 | Collen Kusy | Robert W. Baird | $14.00 | $5.56 | 151.80% | 1700.41% |
Mar 10, 2022 | Brian Abrahams | RBC Capital | $8.00 | $6.49 | 23.27% | 928.81% |
10
Karyopharm Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $3.00 |
Last Closing Price | $0.78 | $0.78 | $0.78 |
Upside/Downside | -100.00% | -100.00% | 285.80% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 06, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 10, 2024 | RBC Capital | Outperform | Outperform | Hold |
Jan 10, 2023 | SVB Leerink | Market Perform | Market Perform | Hold |
Nov 04, 2022 | RBC Capital | Sector Perform | Outperform | Upgrade |
Mar 10, 2022 | RBC Capital | Sector Perform | Sector Perform | Hold |
10
Karyopharm Therapeutics Financial Forecast
Karyopharm Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $36.01M | $37.58M | $38.70M | $33.58M | $36.15M | $39.68M | $47.67M | $126.27M | $37.69M | $22.60M | $23.26M | $35.10M | $21.33M | $33.51M | $18.14M | $18.10M | $13.15M | $9.49M | $155.00K | $10.00M | $68.00K |
Avg Forecast | $50.30M | $49.60M | $49.50M | $45.70M | $38.21M | $37.92M | $36.21M | $34.48M | $35.40M | $37.27M | $35.67M | $36.32M | $34.43M | $34.83M | $35.96M | $34.41M | $52.71M | $26.21M | $26.30M | $25.89M | $28.61M | $23.02M | $28.41M | $21.47M | $16.34M | $2.77M | $106.00K | $364.56K | $7.95M | $64.17K |
High Forecast | $51.74M | $51.02M | $50.92M | $47.01M | $40.86M | $38.02M | $36.21M | $34.48M | $36.42M | $37.27M | $36.69M | $37.36M | $35.41M | $34.83M | $35.96M | $34.41M | $52.71M | $26.21M | $26.30M | $25.89M | $28.61M | $23.02M | $28.41M | $21.47M | $16.34M | $2.77M | $106.00K | $364.56K | $9.54M | $77.00K |
Low Forecast | $48.72M | $48.04M | $47.95M | $44.27M | $35.78M | $37.83M | $36.21M | $34.48M | $34.29M | $37.27M | $34.55M | $35.18M | $33.35M | $34.83M | $35.96M | $34.41M | $52.71M | $26.21M | $26.30M | $25.89M | $28.61M | $23.02M | $28.41M | $21.47M | $16.34M | $2.77M | $106.00K | $364.56K | $6.36M | $51.33K |
# Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.97% | 1.05% | 1.07% | 0.98% | 1.04% | 1.10% | 1.39% | 2.40% | 1.44% | 0.86% | 0.90% | 1.23% | 0.93% | 1.18% | 0.84% | 1.11% | 4.74% | 89.56% | 0.43% | 1.26% | 1.06% |
Forecast
Karyopharm Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
EBITDA | - | - | - | - | - | - | - | - | - | $-31.26M | $-29.57M | $-28.31M | $-32.55M | $-30.16M | $-42.48M | $-34.41M | $46.68M | $-43.51M | $-48.22M | $-51.94M | $-36.03M | $-46.41M | $-39.29M | $-46.11M | $-41.68M | $-38.01M | $-40.08M | $-62.91M | $-38.28M | $-29.71M |
Avg Forecast | $-41.85M | $-41.27M | $-41.18M | $-38.02M | $-31.79M | $-31.55M | $-30.13M | $-41.01M | $-29.46M | $-31.01M | $-29.68M | $-37.28M | $-28.64M | $-29.54M | $-30.50M | $-39.87M | $-44.70M | $-22.23M | $-22.30M | $-47.55M | $-24.26M | $-19.52M | $-24.10M | $-40.10M | $-13.86M | $-2.35M | $-89.89K | $-47.00M | $-28.40M | $-27.94M |
High Forecast | $-40.54M | $-39.97M | $-39.89M | $-36.83M | $-29.77M | $-31.47M | $-30.13M | $-32.80M | $-28.53M | $-31.01M | $-28.75M | $-29.82M | $-27.75M | $-29.54M | $-30.50M | $-31.90M | $-44.70M | $-22.23M | $-22.30M | $-38.04M | $-24.26M | $-19.52M | $-24.10M | $-32.08M | $-13.86M | $-2.35M | $-89.89K | $-37.60M | $-22.72M | $-22.35M |
Low Forecast | $-43.05M | $-42.45M | $-42.36M | $-39.11M | $-34.00M | $-31.63M | $-30.13M | $-49.21M | $-30.30M | $-31.01M | $-30.53M | $-44.73M | $-29.46M | $-29.54M | $-30.50M | $-47.84M | $-44.70M | $-22.23M | $-22.30M | $-57.06M | $-24.26M | $-19.52M | $-24.10M | $-48.12M | $-13.86M | $-2.35M | $-89.89K | $-56.40M | $-34.08M | $-33.52M |
Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 0.76% | 1.14% | 1.02% | 1.39% | 0.86% | -1.04% | 1.96% | 2.16% | 1.09% | 1.49% | 2.38% | 1.63% | 1.15% | 3.01% | 16.17% | 445.82% | 1.34% | 1.35% | 1.06% |
Forecast
Karyopharm Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
Net Income | - | - | - | - | - | - | - | - | - | $-34.51M | $-32.63M | $-34.13M | $-38.51M | $-36.32M | $-49.06M | $-41.40M | $38.72M | $-51.81M | $-53.58M | $-57.41M | $-43.42M | $-53.49M | $-46.43M | $-52.93M | $-48.65M | $-41.37M | $-43.41M | $-66.16M | $-38.46M | $-29.92M |
Avg Forecast | $-23.75M | $-22.50M | $-20.00M | $-25.00M | $-30.89M | $-32.86M | $-37.24M | $-49.34M | $-38.75M | $-35.00M | $-42.78M | $-44.85M | $110.58M | $-87.34M | $-97.80M | $-47.97M | $-69.88M | $-103.98M | $-115.05M | $-52.56M | $-91.42M | $-108.56M | $-89.72M | $-46.03M | $-103.46M | $-127.59M | $-151.98M | $-49.43M | $-28.53M | $-28.13M |
High Forecast | $-22.78M | $-21.58M | $-19.19M | $-23.98M | $-23.48M | $-31.52M | $-35.72M | $-39.47M | $-34.74M | $-33.58M | $-41.04M | $-35.88M | $132.69M | $-87.34M | $-97.80M | $-38.38M | $-69.88M | $-103.98M | $-115.05M | $-42.05M | $-91.42M | $-108.56M | $-89.72M | $-36.82M | $-103.46M | $-127.59M | $-151.98M | $-39.54M | $-22.83M | $-22.50M |
Low Forecast | $-24.63M | $-23.34M | $-20.75M | $-25.93M | $-37.07M | $-34.08M | $-38.62M | $-59.20M | $-44.10M | $-36.30M | $-44.37M | $-53.82M | $88.46M | $-87.34M | $-97.80M | $-57.56M | $-69.88M | $-103.98M | $-115.05M | $-63.07M | $-91.42M | $-108.56M | $-89.72M | $-55.23M | $-103.46M | $-127.59M | $-151.98M | $-59.32M | $-34.24M | $-33.76M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 0.76% | 0.76% | -0.35% | 0.42% | 0.50% | 0.86% | -0.55% | 0.50% | 0.47% | 1.09% | 0.47% | 0.49% | 0.52% | 1.15% | 0.47% | 0.32% | 0.29% | 1.34% | 1.35% | 1.06% |
Forecast
Karyopharm Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
SG&A | - | - | - | - | - | - | - | - | - | $30.80M | $34.48M | $35.91M | $34.65M | $34.65M | $37.34M | $38.77M | $34.56M | $35.10M | $36.53M | $37.65M | $33.93M | $30.97M | $30.84M | $30.68M | $28.39M | $25.27M | $24.66M | $27.10M | $7.62M | $6.26M |
Avg Forecast | $62.99M | $62.12M | $61.99M | $57.23M | $47.85M | $47.50M | $45.35M | $43.18M | $44.34M | $46.68M | $44.67M | $45.48M | $43.12M | $43.62M | $45.04M | $43.09M | $66.02M | $32.83M | $32.94M | $32.43M | $35.83M | $28.83M | $35.58M | $26.88M | $20.46M | $3.47M | $132.75K | $456.56K | $5.65M | $80.36K |
High Forecast | $64.80M | $63.89M | $63.77M | $58.87M | $51.17M | $47.62M | $45.35M | $43.18M | $45.61M | $46.68M | $45.95M | $46.79M | $44.35M | $43.62M | $45.04M | $43.09M | $66.02M | $32.83M | $32.94M | $32.43M | $35.83M | $28.83M | $35.58M | $26.88M | $20.46M | $3.47M | $132.75K | $456.56K | $6.79M | $96.43K |
Low Forecast | $61.02M | $60.17M | $60.05M | $55.44M | $44.81M | $47.38M | $45.35M | $43.18M | $42.95M | $46.68M | $43.27M | $44.06M | $41.76M | $43.62M | $45.04M | $43.09M | $66.02M | $32.83M | $32.94M | $32.43M | $35.83M | $28.83M | $35.58M | $26.88M | $20.46M | $3.47M | $132.75K | $456.56K | $4.52M | $64.29K |
Surprise % | - | - | - | - | - | - | - | - | - | 0.66% | 0.77% | 0.79% | 0.80% | 0.79% | 0.83% | 0.90% | 0.52% | 1.07% | 1.11% | 1.16% | 0.95% | 1.07% | 0.87% | 1.14% | 1.39% | 7.28% | 185.77% | 59.36% | 1.35% | 77.95% |
Forecast
Karyopharm Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 12 |
EPS | - | - | - | - | - | - | - | - | - | $-0.30 | $-0.29 | $-0.30 | $-0.43 | $-0.45 | $-0.62 | $-0.53 | $0.51 | $-0.69 | $-0.71 | $-0.77 | $-0.59 | $-0.73 | $-0.63 | $-0.78 | $-0.76 | $-0.67 | $-0.71 | $-1.09 | $-0.78 | $-0.71 |
Avg Forecast | $-0.19 | $-0.18 | $-0.16 | $-0.20 | $-0.25 | $-0.26 | $-0.30 | $-0.33 | $-0.31 | $-0.28 | $-0.34 | $-0.37 | $-0.35 | $-0.57 | $-0.63 | $-0.63 | $-0.45 | $-0.67 | $-0.74 | $-0.71 | $-0.59 | $-0.70 | $-0.58 | $-0.69 | $-0.67 | $-0.83 | $-0.98 | $-0.87 | $-0.46 | $-0.63 |
High Forecast | $-0.18 | $-0.17 | $-0.15 | $-0.19 | $-0.19 | $-0.25 | $-0.29 | $-0.32 | $-0.28 | $-0.27 | $-0.33 | $-0.35 | $-0.34 | $-0.57 | $-0.63 | $-0.63 | $-0.45 | $-0.67 | $-0.74 | $-0.71 | $-0.59 | $-0.70 | $-0.58 | $-0.69 | $-0.67 | $-0.83 | $-0.98 | $-0.87 | $-0.37 | $-0.50 |
Low Forecast | $-0.20 | $-0.19 | $-0.17 | $-0.21 | $-0.30 | $-0.27 | $-0.31 | $-0.35 | $-0.35 | $-0.29 | $-0.35 | $-0.38 | $-0.37 | $-0.57 | $-0.63 | $-0.63 | $-0.45 | $-0.67 | $-0.74 | $-0.71 | $-0.59 | $-0.70 | $-0.58 | $-0.69 | $-0.67 | $-0.83 | $-0.98 | $-0.87 | $-0.55 | $-0.76 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.07% | 0.85% | 0.82% | 1.22% | 0.80% | 0.98% | 0.84% | -1.13% | 1.02% | 0.95% | 1.09% | 1.00% | 1.04% | 1.08% | 1.12% | 1.13% | 0.81% | 0.72% | 1.25% | 1.70% | 1.13% |
Forecast
Karyopharm Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BLUE | bluebird bio | $0.30 | $14.13 | 4610.00% | Hold |
PMVP | PMV Pharmaceuticals | $1.61 | $18.00 | 1018.01% | Buy |
XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
KPTI | Karyopharm Therapeutics | $0.78 | $7.33 | 839.74% | Buy |
CTMX | CytomX Therapeutics | $0.87 | $5.73 | 558.62% | Buy |
GOSS | Gossamer Bio | $0.66 | $3.75 | 468.18% | Buy |
ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
NUVB | Nuvation Bio | $2.70 | $6.75 | 150.00% | Buy |
ASMB | Assembly Biosciences | $14.72 | $35.50 | 141.17% | Buy |
REPL | Replimune Group | $11.05 | $24.20 | 119.00% | Buy |
KRON | Kronos Bio | $0.87 | $1.63 | 87.36% | Buy |
MREO | Mereo BioPharma Group | $3.68 | $6.75 | 83.42% | Buy |
MRSN | Mersana Therapeutics | $1.98 | $3.00 | 51.52% | Buy |
HOOK | HOOKIPA Pharma | $2.30 | $3.00 | 30.43% | Buy |
AGIO | Agios Pharmaceuticals | $55.54 | $48.00 | -13.58% | Buy |